Johnson & Johnson (JNJ.US) has increased the settlement amount for the baby powder carcinogenic lawsuit to over $8.2 billion.
According to informed sources, Johnson & Johnson has increased the settlement amount for thousands of lawsuits accusing its baby powder of causing cancer to over $8.2 billion, compared to the previously proposed settlement amount of $6.5 billion.
According to sources familiar with the matter, Johnson & Johnson has increased the settlement amount for thousands of lawsuits alleging its baby powder causes cancer to over $8.2 billion, up from the previous offer of $6.5 billion. The decision to increase the settlement amount will bring the total amount the company has agreed to pay or has already paid to resolve baby powder-related lawsuits to over $13.4 billion.
Sources added that under the new terms, claimants may receive higher compensation as well as approximately $650 million in legal fees. Settlement negotiations are ongoing.
Johnson & Johnson maintains that talcum powder (now discontinued) has never been proven to cause cancer. The company recently obtained agreements from over 75% of the plaintiffs in baby powder-related lawsuits to reach out-of-court settlement agreements.
If more plaintiffs accept the agreement, it will help Johnson & Johnson expedite bankruptcy proceedings, confining liability to a subsidiary established to settle legal claims. The company may reportedly file for bankruptcy in the coming days.
Johnson & Johnson has also resolved 95% of allegations regarding its baby powder being contaminated with asbestos and causing mesothelioma, a type of cancer affecting the lungs, heart, and other organ tissues.
Related Articles
CF PHARMTECH (02652) expects to achieve a adjusted net profit of approximately 30-35 million yuan in 2025, with stable business operations and continuous progress in innovative research and development.

US Stock Market Move | HSBC Holdings (HSBC.US) fell more than 2% amid reports of plans to cut 20,000 jobs over the next few years.

Service business cooling can't hide strong hardware performance! Morgan Stanley: Apple Inc. (AAPL.US) iPhone production increases significantly, shipments may exceed market expectations.
CF PHARMTECH (02652) expects to achieve a adjusted net profit of approximately 30-35 million yuan in 2025, with stable business operations and continuous progress in innovative research and development.
US Stock Market Move | HSBC Holdings (HSBC.US) fell more than 2% amid reports of plans to cut 20,000 jobs over the next few years.

Service business cooling can't hide strong hardware performance! Morgan Stanley: Apple Inc. (AAPL.US) iPhone production increases significantly, shipments may exceed market expectations.

RECOMMEND

State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026

Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026

Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026


